NCT01585350 - A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

October 31, 2014

Conditions

Melanoma

Interventions

BIOLOGICAL

MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)

"Cohort 1 will be divided into three sub-groups and will receive:~* Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)~* Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1~* Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations"

BIOLOGICAL

MELITAC 12.1 + Montanide ISA-51 + polyICLC

"Cohort 2 will be divided into three sub-groups and will receive:~* Group 2a: MELITAC 12.1 + polyICLC adjuvant~* Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1~* Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations"

Trial Locations (1)

22908

University of Virginia, Charlottesville